 |
|
|
Home > Business Opportunities > Recent Collaborations
| December 21, 2009 | |
A LOI was recently signed between Yongnam Kim and Do-Coop regarding the licensing of the manufacturing, marketing and distribution of NeoCyclosporine for ophthalmic use in Korea. Cyclosporine is an effective immunosuppressive, anti-inflammatory, and anti-parasitic agent widely used for dry-eye syndrome. It was successfully formulated with Neowater. This formulation is eligible for new IP. Under this agreement Yongnam Kim shall pay Do-Coop milestone payments and royalties from the sales of the licensed product.
|
|
| July 16, 2009 | |
|
A licensing agreement recently signed between Champion Biotechnology Inc. and Do-Coop Technologies Ltd. deals with SG410, a novel benzoyl-phenylurea-sulfur analogue, which was found to be efficient as an anti-pancreatic cancer drug candidate via its use as a cancer cell proliferation inhibitor. However, it could only be deployed in a highly toxic solvent, unfit for clinical trials. Formulating SG410 with Neowater maintains its in-vitro and in-vivo efficacy and mechanism of action with sharply reduced toxicity, which is critical for clinical use. (Press release)
|
|
